Gamma emitting, CCK-A antagonists for pancreatic imaging

Details Gamma emitting, CCK-A antagonists for pancreatic imaging Gamma emitting, CCK-A antagonists for pancreatic imaging

1990-03-05

1991-02-19

Maples, John S.

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

540509, A61K 4902, C07D24324

Patent

active

049942581

ABSTRACT:
Novel radiolabeled cholecystokinin-A (CCK-A) antagonists have been developed which, after intravenous injection, localize in the pancreas as a result of specific binding to CCK-A receptors. These tracers, when labeled with appropriate radiohalogens, are useful as commercial diagnostic imaging radiopharmaceuticals and radiotherapeutic drugs.

REFERENCES:
patent: 4528177 (1985-07-01), Molloy et al.
patent: 4628084 (1986-12-01), Bock et al.
patent: 4820834 (1989-04-01), Evans et al.
Yamamoto et al., J. Nuclear Medicine, 26, pp. 765-769 (1985).
Frost et al., J. Nuclear Medicine, 30, pp. 849-850, No. 503 (1989).
Burns et al., J. Nuclear Medicine, 30, p. 931, No. 858 (1989).

Affiliated with

Also associated with

Rating

Gamma emitting, CCK-A antagonists for pancreatic imaging does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Gamma emitting, CCK-A antagonists for pancreatic imaging, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gamma emitting, CCK-A antagonists for pancreatic imaging will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1142177